US · ATTO · BIOTECHNOLOGY
Attovia Therapeutics, Inc. (ATTO) intrinsic value and stock valuation
$22.14as of 2026-09-18 · Mkt cap 957.42M
Data updated · price as of 2026-09-18
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Attovia Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values ATTO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ATTO’s statements →
Attovia Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2025–2024, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| FY | FY | |
|---|---|---|
| Revenue | $1.35T | $0.00 |
| Operating income | -$-67.16T | -$-41.55T |
| Net income | -$-60.63T | -$-39.8T |
| EPSd | -$-1.41M | -$-924.98K |
| Operating cash flow | -$-59.2T | -$-35.04T |
| Capital expenditure | -$-2.31T | -$-1.77T |
| Free cash flow | -$-61.51T | -$-36.81T |
| Total assets | $165.9T | $76.7T |
| Total debt | $5.26T | $0.00 |
| Net debt | -$-34.93T | -$-30.63T |
| Total equity | $150.8T | $62.1T |
| Cash and short-term investments | $152.3T | $69.3T |
Income statement
| FY | FY | |
|---|---|---|
| Revenue | $1.35T | $0.00 |
| Cost of revenue | $804B | $313B |
| Gross profit | $546B | -$-313B |
| Research and development expenses | $54.2T | $33.9T |
| Selling, general and administrative expenses | $13.6T | $7.38T |
| Other expenses | $0.00 | $0.00 |
| Operating expenses | $67.7T | $41.2T |
| Cost and expenses | $68.5T | $41.6T |
| Interest income | $6.63T | $3.44T |
| Interest expense | $0.00 | $0.00 |
| Depreciation and amortization | $804B | $313B |
| Ebitda | -$-66.36T | -$-41.24T |
| Operating income | -$-67.16T | -$-41.55T |
| Total other income/expenses, net | $6.53T | $1.75T |
| Income before tax | -$-60.63T | -$-39.8T |
| Income tax expense | $0.00 | $0.00 |
| Net income | -$-60.63T | -$-39.8T |
| Weighted average shares outstanding | $43T | $43T |
| Weighted average diluted shares outstanding | $43T | $43T |
Balance sheet
| FY | FY | |
|---|---|---|
| Cash and short-term investments | $152.3T | $69.3T |
| Net receivables | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 |
| Total current assets | $156.3T | $72.5T |
| Property, plant and equipment, net | $7.87T | $3.23T |
| Goodwill and intangible assets | $0.00 | $0.00 |
| Long-term investments | $404B | $607B |
| Total non-current assets | $9.6T | $4.23T |
| Total assets | $165.9T | $76.7T |
| Accounts payable | $3.55T | $4.14T |
| Short-term debt | $1.92T | $0.00 |
| Deferred revenue | $450B | $0.00 |
| Total current liabilities | $11T | $7.72T |
| Long-term debt | $3.34T | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 |
| Total non-current liabilities | $4.1T | $6.87T |
| Capital lease obligations | $3.34T | $0.00 |
| Total liabilities | $15.1T | $14.6T |
| Common stock | $1B | $1B |
| Retained earnings | -$-111.01T | -$-50.38T |
| Accumulated other comprehensive income (loss) | $99B | $67B |
| Total equity | $150.8T | $62.1T |
| Total investments | $112.5T | $39.3T |
| Total debt | $5.26T | $0.00 |
| Net debt | -$-34.93T | -$-30.63T |
Cash flow statement
| FY | FY | |
|---|---|---|
| Net income | -$-60.9T | -$-45.05T |
| Depreciation and amortization | $804B | $313B |
| Stock-based compensation | $0.00 | $0.00 |
| Change in working capital | $276B | $1.54T |
| Accounts receivable | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 |
| Accounts payable | $180B | $1.72T |
| Net cash provided by operating activities | -$-59.2T | -$-35.04T |
| Investments in property, plant and equipment | -$-2.31T | -$-1.77T |
| Acquisitions, net | $0.00 | $0.00 |
| Net cash used for investing activities | -$-73.46T | -$-39.8T |
| Common stock issued | $142T | $82.9T |
| Common stock repurchased | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 |
| Net cash used for financing activities | $142T | $82.7T |
| Net change in cash | $9.56T | $30.6T |
| Cash at end of period | $40.2T | $30.6T |
| Operating cash flow | -$-59.2T | -$-35.04T |
| Capital expenditure | -$-2.31T | -$-1.77T |
| Free cash flow | -$-61.51T | -$-36.81T |
Line items
Line items
Line items
About Attovia Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
- CEO
- Tao Fu
- Employees
- 44
- Beta
- 0.00
Explore
Frequently asked questions
What is the intrinsic value of Attovia Therapeutics, Inc. (ATTO)?
Attovia Therapeutics, Inc. (ATTO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ATTO undervalued?
ATTO trades at a price of $22.14 (Sep 19, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.